VolitionRx Limited - SIC # 3850 -

Ticker Exchange SIC # Website Latest Ticker
VNRX NYSE American 3850 volition.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for VolitionRx Limited

VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update - May 11th, 2026 6:19 am
VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats - May 6th, 2026 6:17 am
Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing - Apr 29th, 2026 6:17 am
VNRX: Zacks SCR Refreshes its Latest Report With Volition's Financials, Prices, EPS Estimates, Market Statistics and Target Price Adjusted for 1-for-20 Reverse-Split - Apr 28th, 2026 3:10 am
VNRX: Upcoming Milestones Expected in 2026; Year-End 2025 Results. Special Meeting of Stockholders Approves Reverse-Split. Subsequently, the Board of Directors authorized a 1-for-20 reverse-split that will become effective on April 28th. - Apr 27th, 2026 5:18 am
VolitionRx Announces Acceptance of Compliance Plan by NYSE American - Apr 23rd, 2026 6:12 am
Volition Launches rNuQ™ Webshop Broadening Product Range - Apr 20th, 2026 5:30 am
VolitionRX Ltd (VNRX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Apr 2nd, 2026 7:01 pm
VolitionRx Limited Q4 2025 Earnings Call Summary - Apr 1st, 2026 6:30 am
VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update - Mar 31st, 2026 2:05 pm
VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium - Mar 31st, 2026 6:16 am
Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma Patients - Mar 30th, 2026 6:13 am
Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference - Mar 26th, 2026 6:17 am
VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update - Mar 25th, 2026 2:12 pm
Volition Announces Detection of Over 95% of Early-Stage Cancers - Mar 25th, 2026 6:17 am
Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA - Mar 18th, 2026 6:17 am
VNRX: Review of Recent Events by Pillar; 4Q & Year End 2025 Results Expected in late March; Special Meeting of Stockholders to be held on March 31st to approve reverse-split. Almost US$2 million in cash funding received through the issuance of Convertible Note. - Mar 9th, 2026 4:33 am
VolitionRx announces automated Nu.Q Vet Cancer Test with Fujifilm Vet Systems - Mar 7th, 2026 6:18 am
Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems - Mar 6th, 2026 6:10 am
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution - Feb 25th, 2026 6:10 am